



# Méthodes et structuration des futurs appels à projets du Défi 1 "Health, demographic change and wellbeing "

## Horizon 2020

Séminaire d'été  
GDR Longévité et vieillissement  
25 septembre 2015

Arnaud de Guerra  
Mission Prospective et recherche  
Direction générale de la santé

# SOMMAIRE

## **1. Genèse de Horizon 2020 et du programme de travail 2016 – 2017**

- La décision du Conseil: programme stratégique
- Consultations pour l'élaboration du programme de travail 2016-2017

## **2. Présentation du Programme de travail 2016-2017**

- Le vieillissement comme thème majeur du programme
- Le vieillissement dans les autres thèmes

## **3. Prise en compte des remontées et enseignements pour le prochain programme 2018-2019**

# Opportunités de financements EU en R&I (Santé)



**Commission  
Européenne**

Sujets ouverts  
**Sujets ciblés-  
marché  
Sujets  
« sociétaux »**



**Innovative Medicine  
Initiative**

**Partenariat  
public-privé  
CE + EFPIA**

**Dvpt nouvelles  
molécules  
thérapeutiques**



**European-Developing  
Countries Clinical Trials  
Partnership**

**Partenariat  
public-public  
EM + CE +  
E.Africains**

**Essais cliniques  
sur les maladies  
infectieuses en  
collaboration  
NORD-SUD**

**Programmation  
Conjointe**

**Joint Programming  
Initiative**

**Consortia  
D'Etats-  
Membres**

**Thématiques  
Variées/  
Standardisation  
des Agendas  
de recherche**

**ERA-NETs**

**Appels  
transnationaux**



# Genèse du programme stratégique Horizon 2020 et du programme de travail 2016 – 2017

# Horizon 2020: l'unique programme de recherche et d'innovation de l'UE

2007-2013



2014-2020



## Le programme de financement H2020

- Pour la période 2014-2020
- Finance des projets interdisciplinaires susceptibles de répondre aux grands défis économiques et sociaux
- Il a comme objectif de couvrir l'ensemble de la chaîne de l'innovation
- Il concentre ses financements sur l'excellence scientifique, la primauté industrielle et les défis sociétaux
- Décision du Conseil européen 20 décembre 2013

# Mise en œuvre



Programme stratégique

*Proposition  
Commission,  
adoption  
Parlement et  
Conseil  
Commission*

Programme de travail

*Consultation des Etats*

2014

2015

2016

2017

2018

2019

2020

1<sup>er</sup> programme stratégique

<1<sup>er</sup> programme de travail >

2<sup>ème</sup> programme stratégique

< 2<sup>ème</sup> PT >

3<sup>ème</sup> programme stratégique

< 3<sup>ème</sup> PT >

> < 4<sup>ème</sup> PT >

## Contexte du défi Santé

- Changement démographique, population vieillissante
- Accroissement du fardeau des maladies non-transmissibles/ « lifestyle »
- Augmentation du coût de la santé & de la pression sur les systèmes de santé
- Augmentation des coûts du développement des médicaments, vaccins, dispositifs médicaux...
- Insuffisance d'évidences sur les avantages et l'efficacité, des approches et pratiques actuelles

- **Promouvoir le vieillissement actif et en bonne santé**
- **Favoriser une approche « tout au long de la vie »**
- **Réduire les inégalités dans le domaine de la santé**
- volonté de « scale-up »
- Soutenir le transfert vers la clinique, soutien aux PME et industrie du secteur
- Utilisation des infrastructures européennes



# La d cision du 20 d cembre 2013

20.12.2013	EN	Official Journal of the European Union	L 347/965
<b>DECISIONS</b>			
<b>COUNCIL DECISION</b>			
<b>of 3 December 2013</b>			
<b>establishing the specific programme implementing Horizon 2020 - the Framework Programme for Research and Innovation (2014-2020) and repealing Decisions 2006/971/EC, 2006/972/EC, 2006/973/EC, 2006/974/EC and 2006/975/EC</b>			
(Text with EEA relevance)			
(2013/743/EU)			
THE COUNCIL OF THE EUROPEAN UNION,	(2)	The general objective of Horizon 2020 should be pursued through three priorities dedicated to generating excellent science ("Excellent science"), creating industrial leadership ("Industrial leadership") and tackling societal challenges ("Societal challenges"). The general objective should also be pursued through the specific objectives "Spreading excellence and widening participation" and "Science with and for society". Those priorities and specific objectives should be implemented by means of a specific programme setting out one Part for each of the three priorities, one Part for the specific objective "Spreading excellence and widening participation", one Part for the specific objective "Science with and for society" and one Part for the non-nuclear direct actions of the Joint Research Centre (JRC).	
Having regard to the Treaty on the Functioning of the European Union, and in particular Article 182(4) thereof,			
Having regard to the proposal from the European Commission,			
After transmission of the draft legislative act to the national parliaments,			
Having regard to the opinion of the European Parliament,			
Having regard to the opinion of the European Economic and Social Committee <sup>(1)</sup> ,	(3)	All Horizon 2020 priorities and specific objectives should include an international dimension. International cooperation activities should be maintained at least at the level of the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007-2013) ("Seventh Framework Programme"), adopted by Decision No 1982/2006/EC of the European Parliament and of the Council <sup>(2)</sup> .	
Having regard to the opinion of the Committee of the Regions <sup>(3)</sup> ,			
Acting in accordance with a special legislative procedure,			
Whereas:	(4)	While Regulation (EU) No 1291/2013 sets out the general objective of Horizon 2020, the priorities and the broad lines of the specific objectives and activities to be carried out, the specific programme should define the specific objectives and the broad lines of the activities which are specific to each of the Parts. The provisions on implementation set out in Regulation (EU) No 1291/2013 apply fully to the specific programme, including those relating to ethical principles.	
(1) In accordance with Article 182(3) of the Treaty on the Functioning of the European Union (TFEU), the Framework Programme for Research and Innovation 2014-2020 ("Horizon 2020"), established by Regulation (EU) No 1291/2013 of the European Parliament and of the Council of 11 December 2013 <sup>(4)</sup> , is to be implemented through a specific programme which determines the specific objectives and rules for their implementation, fixes its duration and provides for the means deemed necessary.	(5)	Each Part should be complementary to and implemented in a coherent way with the other Parts of the specific programme.	
<sup>(1)</sup> OJ C 181, 21.6.2012, p. 111.			
<sup>(2)</sup> OJ C 277, 13.9.2012, p. 143.			
<sup>(3)</sup> Regulation (EU) No 1291/2013 of the European Parliament and of the Council of 11 December 2013 establishing Horizon 2020 - the Framework Programme for Research and Innovation (2014-2020) and repealing Decision No 1982/2006/EC (See page 104 of this Official Journal).			
	<sup>(4)</sup> Decision No 1982/2006/EC of the European Parliament and of the Council of 18 December 2006 concerning the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007-2013) (OJ L 412, 30.12.2006, p. 1).		

- Social sciences and humanities will be fully integrated in each of the specific objectives of H2020
- This includes: understanding the determinants of health and optimising the effectiveness of Health care provision

# La Décision du 20 décembre 2013

## Challenge 1: Health, demographic change and well-being

“It is a societal challenge to adjust to the further demands on health and care sectors due to the ageing population (...) . A better understanding of ageing processes and the prevention of age-related illnesses are the basis for keeping European citizens healthy and active throughout the course of their lives”

### 1.4.1 Ageing and independent and assisted living

“Multidisciplinary advanced and applied research and innovation with socioeconomic, behavioural, gerontological, digital and other sciences is needed for cost effective user-friendly solutions for active, independent and assisted daily for the ageing population”

# Challenge 1: autres lignes

- 1.1.1 Understanding the determinants of health, improving health promotion and disease prevention
- 1.4.2 Individual awareness and improvement and empowerment for self management of health
- 1.5.1 Improving health information and better use of health data
- 1.5.2 Improving scientific tools and methods to support policy making and regulatory needs
- 1.6.1 Promoting integrated care
- 1.6.2 Optimising the efficiency and effectiveness of healthcare provision and reducing inequalities by evidence-based decision making and dissemination of best practice, and innovation technologies and approaches

# Traduction du programme stratégique en programme de travail

## L'exemple du PT 2016-2017






Advisory Group

Consultations  
publiques, séminaires...

Consultations états  
membre


**PRINTEMPS  
2014**



**Horizon 2020 Strategic Programming Document  
Guidance for the development of the Work Programme  
2016-2017**

# Traduction du programme stratégique en programme de travail

## L'exemple du PT 2016-2017






# Présentation du Programme de Travail 2016-2017

# Défi SANTE – WP 2016-2017

## Focus Personalized Medicine (PM)



## Understanding health, well-being and disease

Budg  
projet      Budget  
total      Type

PM	Year	Title	Budg projet	Budget total	Type
PM01	2016	<b>Multi omics for personalised therapies adressing diseases of the immune system</b>	12-15	30	RIA
		<p>Integrate and use high quality genome-epigenome-metabolome-microbiome data from large international initiative with innovative imaging, structural, lifestyle/environmental data + disease oriented analysis&gt;&gt;understanding health&amp;disease</p> <ul style="list-style-type: none"> <li>- Relevant biomarkers for clinical validation → targeted therapies for complex diseases.</li> <li>- International cooperation</li> </ul>			
PM02	2017	<b>New concepts in patient stratification</b>	4-6	40	RIA
		<p>A majority of drugs effective in a limited n. of patients = New concepts for disease based PS for personalised interventions Integrate –omics, modelling, longitudinal data</p> <ul style="list-style-type: none"> <li>- to be validated in pre-clinical/clinical studies</li> </ul>			
PM03	2017	<b>Diagnostic characterisation of rare diseases</b>	10-15	15	RIA
		<p>Apply genomics or other-omics to molecular characterisation of undiagnosed RD. Lien IRDiRC. &gt;&gt;molecular diagnosis of large n. of RD</p> <ul style="list-style-type: none"> <li>- Genetic variability</li> <li>- Classification of RD: common standards &amp; terminologies , classif. Bioinfo tools (large scale project)</li> </ul> <p>Molecular/functional characterization to confirm diagnosis</p>			
PM04	2016	<b>Networking and optimising the use of population and patient cohorts at EU level</b>	8-10	30	RIA
		<ul style="list-style-type: none"> <li>- Maximize exploitation of Population cohorts . Use ICT, new type of data &gt;&gt; provide knowledge on health disease determinants, course of disease etc</li> <li>- Link with INFRA, international initiatives- facilitate hypothesis-driven research</li> <li>- Support to Health policy</li> </ul>			



## Preventing disease

Budget  
projet    Bud  
total    Type

PM	Year	Project Name	Budget projet	Bud total	Type
PM05	2016	<i>The European Human Biomonitoring Initiative</i>	50	50	EJP
PM06	2016	<i>Vaccine development for malaria and/or neglected infectious diseases</i>	3 à 5 15 à 20	40	RIA




### preclinical and early clinical development of new vaccine candidates (antigens/adjuvants)

- A) large platforms >>advances in vaccinology** (e.g. in silico analysis and novel in vitro and in vivo immunoscreens) or new approaches for the discovery and selection of novel, appropriately immunogenic antigens, and/or novel formulations/combinations for the generation of new vaccine candidates.
- B) Include a systematic approach and define key gate-criteria for selection across each step of the research and development pipeline
- C) **SMALLER PROPOSALS = focus on one disease or one vaccine candidate (similar innovative/comprehensive approach).**

PM07	2017	<i>Promoting mental well-being in the young</i>	2-4	20	RIA
------	------	---	-----	----	-----

- Population-oriented primary prevention interventions to promote mental well-b. Target group: up to 25 years.
- Build on biological, psychological and social determinant of mental well being such as cultural, work life, lifestyle, epidemio, economic, environmental
- Aim at increasing resilience and mitigating the impact of risk factors
- Multi-disciplinary approach.
- Includes the young themselves (empowerment) + relevant stakeholders.
- Gender and health inequality aspects

## Treating and managing diseases

PM08	2017	<i>New therapies for rare diseases</i>	4-6	60	RIA
		<ul style="list-style-type: none"> <li>- Support will be provided to clinical trials on substances where orphan designation has been given by the European Commission (at the submission deadline)</li> <li>- from small molecule to gene or cell therapy, may include novel interventions and/or repurposing of existing and known interventions.</li> </ul>			
PM09	2016	<b><i>New therapies for chronic diseases</i></b>	<b>4-6</b>	<b>60</b>	<b>RIA</b>
		<p>clinical trial(s), for chronic <b>non-communicable or chronic infectious diseases</b></p> <p>&gt;&gt;supporting proof of concept of clinical safety and efficacy in humans <b>of novel therapies</b> (pharmacological as well as non-pharmacological) or the optimisation of available therapies</p>			
PM10	2017	<i>Comparing the effectiveness of existing healthcare interventions in the adult population</i>	4-6	40	RIA
		<p>Compare the use of currently <b>available preventative or therapeutic</b> (pharmacological as well as non-pharmacological) healthcare interventions in adults (elderly not excluded)</p> <ul style="list-style-type: none"> <li>- Address conditions that are : frequent, may lead to co-morbidities, have a high negative impact on the quality of life of the individual, high costs&gt;&gt; make recommendations</li> </ul> <p>Assessment of health and socio-economic outcomes (e.g. quality of life, patient mortality, morbidity, costs, and performance of the health systems)</p> <ul style="list-style-type: none"> <li>- costs-effectiveness analysis to be done</li> </ul>			
PM11	2016+2017	<b><i>Clinical research on regenerative medicine</i></b>	<b>4-6</b>	<b>30</b>	<b>RIA</b>
		<ul style="list-style-type: none"> <li>- Test NEW regenerative medicine therapies which are ready for clinical (in-patient) research focus on one specific clinical phase of work.</li> </ul>			

**ACTIVE AND HEALTHY AGEING**

PM12	2016	<b>PCP-eHealth innovation in empowering the patient</b>	4	18	PCP
<p>PCP (Pre Commercial Procurement) for R&amp;D of new services / integration of existing services Increasing the level of interactions between the user and the health professional, enabling users to control their health conditions and adhere to prescribed medical plans.</p>					
PM13	2016	<b>PPI for deployment and scaling up of ICT solutions for active and healthy ageing 2-5</b>		9	PPI
<p>Specify, purchase and deploy ICT-based solutions for active and healthy ageing Key document: <del>scaling up road map of the EIP. Co-fund up to 40% of total costs</del></p>					
PM14	2016	<b>EU-JAPAN cooperation on novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities.</b>	2-3	5	RIA
<p>Developing and demonstrating ICT robotics based solutions for <u>extending</u> active and healthy ageing</p> <ul style="list-style-type: none"> <li>- multidisciplinary research (including behaviour/SSH)</li> <li>- Modularity, cost-effectiveness, reliability, flexibility (=adaptation to needs &amp; lifestyle of older people)</li> <li>- Safety and acceptability</li> <li>- Test site in EU and Japan, with sufficient users (for validating)</li> <li>- <del>Max 36 months, no other third country partner, consortium agreement</del></li> </ul>					
PM15	2017	<b>Personalised coaching for well-being and care of people as they age</b>	3-4	26	RIA
<p>= dvppt of radically new concept for a virtual coach (ex diet, physical activity, risk avoidance, leisure.from a physical, mental and cognitive, and social point of view)</p> <ul style="list-style-type: none"> <li>- Take into account gender and ethics aspects.</li> <li>- User-centred. Cost-effectiveness.</li> </ul>					

## Methods and data

PM16	2017	<u>In-silico trials</u> for developing and assessing <u>biomedical products</u>	4-6	19	RIA
<p>To simulate human physiology and physiopathology at the relevant biological level (ex cell, tissue, organism) and the interaction with the product</p> <p>To take into account the variability between individuals (genetics, gender, microbiota etc)</p> <p>To build virtual patients or populations for predicting treatments outcomes &gt;&gt;Personalised medicine</p>					
PM17	2016	<b>Increasing digital security of health related data on a systemic level</b>	4-6	11	RIA
<p>Security related to storage and exchange (including cross-border) of health/personal data protection of personal data and data collected via mobiles</p> <p>Based on existing projects: DECIPHER, open NCP, EPSOS, STORK.</p> <ul style="list-style-type: none"> <li>- Legal &amp; societal aspects (for deployment)</li> <li>- Respect national regulation regarding data protection + standards</li> <li>- <del>To be at least tested in 3 EU MS. Anticipate the <u>technological</u> deployment in other countries</del></li> </ul>					
PM18	2017	Personalised computer models and in-silico systems for well-being	4-6	19	RIA
<p>= dvppt of computer models and simulations systems able to <u>aggregate various informations</u> (biochemical, imaging, medical, lifestyle, ...etc) into <u>robust predictors for resilience and recovery</u></p> <ul style="list-style-type: none"> <li>- Multiscale (time and spatial scales) approach; patient-specific</li> <li>- Multidisciplinary : medicine, SSH and ICT</li> <li>- Based on existing large database (clinical medicine, biomedical/ocupational research, environmental sciences and SSH)</li> </ul>					

## Methods and data

PM19	2016	<b>Big Data supporting Public Health policies [CNECT]</b>	3-5	10	RIA
		<p>= Acquisition, management, sharing, modelling, processing and exploiting big data into integrated solutions to support to health policy (decision marking): ex combined effect of environment, lifestyle and genetics on public health</p> <ul style="list-style-type: none"> <li>- Big data governance</li> <li>- Security and privacy issues</li> </ul>			
PM20	2017	PPI for uptake of standards for the exchange of digitalised healthcare records [CNECT]		8,26	PPI
		EHealth interoperability			
PM21	2017	Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector		9	RIA
		To be developed in a future WS			

## Health care provision and integrated care

PM22	2016	<b>Implementation research for scaling-up of evidence based innovations and good practice</b>	4-6	40	RIA
		<ul style="list-style-type: none"> <li>- Based on implementation research concept = « <i>scientific study of methods to promote the uptake of research findings</i> ».</li> <li>- Selected intervention to be scale up: to make health systems and services <u>more responsive, person-centred, safe, effective and efficient</u>. Large scope (in terms of content + geographical coverage)</li> <li>- Gender issues &amp; Multidisciplinary research</li> <li>- Socio-eco-political analysis to be done + organization and business model of the interventions</li> <li>- Include stakeholders and end-users into the project</li> </ul>			

### Coordination Activities HCO – Health Coordination

- Actions de Coordination et de soutien (CSA):
  - **Médecine personnalisée**
  - Maladies chroniques
  - Soutien aux entreprises/PME en santé (mesures préparatoires, d'accompagnement, notamment TIC/Santé)
- ERA-Net et JPI



<http://www.horizon2020.gouv.fr/pid29768/sante.html>



> NEWSLETTER ET ALERTES



WHO WE ARE ?

# HORIZON 2020

LE PORTAIL FRANÇAIS DU PROGRAMME EUROPÉEN  
POUR LA RECHERCHE ET L'INNOVATION

ESPACE  
EUROPÉEN DE LA  
RECHERCHE

HORIZON 2020

APPELS EN COURS

COMMENT  
PARTICIPER ?

AUTRES  
PROGRAMMES

PME

RECHERCHER...



> Recherche avancée multicritères

Accueil > Horizon 2020 > Défis sociétaux > Santé

## SANTÉ, DÉMOGRAPHIE, BIEN-ÊTRE

### Actualités



28.10.2013

#### Réunions d'information du Point de Contact National (P.C.N.) santé en région

Le P.C.N. santé, en collaboration avec  
les partenaires locaux, organise une  
série de réunions d'information en

#### LE DÉFI SANTÉ

> Présentation

#### LE POINT DE CONTACT NATIONAL

> Présentation et  
contacts

#### AGENDA

27 NOV

ERC : session nationale d'information  
Horizon 2020

PARIS

27 NOV

Actions Marie Skłodowska-Curie :  
session nationale d'information Horizon  
2020

PARIS

# Résumé de l'appel

## Draft accessible:

<https://ec.europa.eu/programmes/horizon2020/en/draft-work-programmes-2016-17>

## Calendrier:

### - Appel 2016:

- Publication (ouverture sur PP): 20 octobre 2015
- Appels en 1 étape surtout, qq 2 étapes
- Dépôts: dates différentes: janvier, février, avril, avril (1ere étape) 2016

### - Appel 2017

- Publication le 20 septembre ou le 8 novembre 2016
- REVERIFIER!**
- Dépôts: janvier, mars, avril 2017

12/02/2016


→ Vérifier dates par ligne dans le WP « conditions for the call »





# Prise en compte des remontées et enseignements pour le prochain programme 2018-2019

# Le dispositif national d'accompagnement à HORIZON 2020



# Le dispositif national d'accompagnement à Horizon 2020

1. Les Représentants français aux comités de programme (RCP) – *action principalement en amont des appels à propositions*
2. Les Groupes Techniques Nationaux (GTN) *action principalement en amont des appels à propositions*
3. Les Points de Contact Nationaux (PCN) *principalement en aval des appels à propositions*

# Les représentant-es auprès des comités de programme

L'avis du comité de programme est nécessaire à :

- L'adoption du programme de travail (bi)annuel
- La sélection des projets avant la phase de négociation des contrats.

Le comité de programme est réuni de 4 à 6 fois par an par la Commission :

Pour chaque configuration du comité de programme, la délégation française est composée d'un représentant du MESR et d'un représentant du ministère technique concerné.

# Les Groupes Thématiques Nationaux

- Chaque RCP constitue un GTN, structure de consultation des acteurs de la recherche (publique et privée) afin de :
- Préparer les positions défendues par la France en comité de programme ;
- Analyser, en lien avec les PCN, les résultats des appels.
- Membres des GTN : Alliances ; Organismes de recherche / Industriels / CPU & représentation sectorielle académique / Syndicats-fédérations professionnelles / Centres techniques représentatifs / Pôles de compétitivité

# Influer en amont sur l'identification des thèmes

- Le travail d'influence au travers des Etats Membres et des Comités de programme est l'une des voies à utiliser
- Ce n'est pas la seule mais il est d'intérêt de la rendre la plus efficace possible
- Un positionnement sur une multitude de priorités est-il « défendable » ?

# Méthodologie interne

- Identification d'un nombre limité de priorités
- Définition en accord avec la nouvelle structuration d'Horizon 2020
- Identification en lien avec les priorités stratégiques

# Remarques

- Liens étroits avec les RCPs
- Ne pas considérer que c'est trop tôt ! En particulier au niveau des alliances
- Alliance : opportunité de définir des priorités transversales en nombre limité
- Travail sur le WP 2018-2019 commence au printemps 2016!



# Format de la consultation initiale

	Recommendation / comment	Expected impact on health, wellbeing and ageing including impact on SMEs, growth, and jobs	1) Gaps addressed (science, technology, markets, policy) and/or 2) New opportunities for people, systems and economy including international linkages	How can interdisciplinarity issues be addressed? (E.g. social sciences, humanities and gender aspects in research, cross-cutting with other societal challenges)
1.1.2	Integrative medicine: role of cell and tissue interactions in health and disease	Main challenges are: 1- to proceed from organ-driven research and medicine towards integrative medicine; 2- to bring a new dimension to the study of disease, integrating high throughput phenotyping and multi-level approaches (gene/chromatin/metabolomics) in research; 3- integrate mathematical treatment of large data-sets; 4- to translate this new knowledge into medical care	Outputs will follow at two levels: 1- a new understanding of disease origin and progression; 2- novel therapeutic approaches Gaps: 1- mathematical innovation and advanced methods for data management; 2- integration of system medicine advances into medical practice that is likely to implicate re-organisation of certain aspects of health care It is absolutely necessary that scientists from main industry and SMEs are involved, since this new approach in biology and medicine has to be paralleled with symmetric shift of approach to new research methods, drug development and innovation in patient care	Interactions between biologists, bio-informaticians and mathematicians will be an absolute requirement
1.1.2	Origin of cancer genome mutations	Improve knowledge on cancer occurrence in general population of environmental exposure and improve observation and la survey	Better understanding of the risks to develop a cancer. Benchmark with international cohorts and behavioral way of life	From fundamental research to social challenges in order to ensure a better understanding.
1.1.2	Understand cancer cells in their niche to better fight tumour growth and metastasis	Knowledge in tumour development through the understanding of its microenvironment within 5 years Knowledge in tumour reaction to treatments through the understanding of its microenvironment during therapy within 5 years New biomarkers of cancer stages related to biochemical composition of the tumour niche within 5 years New targets for anti-cancer drug development within 7 years	The gaps are mainly scientific and technological but latest omics' and cell biological approaches allow to alleviate them. Societal impact may be partly immediate such as to characterize the impact of cancer drugs on tumor microenvironment and more long term to optimize/find new treatments The identification of new cancer biomarkers should be of interest to many SMEs and	Gender aspects need to be addressed with the specificity of sex-specific cancers (breast for instance) with the role of sex hormones (particularly estrogens) as part of the tumor niche components.

## CONCLUSIONS

- Vieillessement principalement traité dans le défi 1 sous ses aspects « technologiques »
- Certains thèmes peuvent (doivent?) comporter des « Work Packages » à tendance SHS
- Reste un Programme de travail 2018-2019
- Doit être préparé très en amont, via les RCP, mais aussi le réseau
- Interactions avec le défi 6 dans prochain programme de travail (cf présentation suivante)?

## Le prix Horizon pour l'Innovation sociale

La Commission européenne a procédé le 16 septembre 2015 à l'ouverture de la [plate-forme de vote en ligne](#) sur le défi sociétal qui fera l'objet du **prix Horizon pour l'innovation sociale**.

Les citoyens sont invités à choisir parmi **cinq challenges** :

- obésité infantile
- vieillissement de la population
- intégration de la population immigrée dans le marché du travail
- les femmes chefs d'entreprise
- citoyens pour une énergie propre

La Commission européenne ouvrira dans un second temps les candidatures pour le prix Horizon pour l'innovation sociale sur la thématique qui aura été **plébiscitée par le public**.

Ce prix, d'une valeur de **2 millions d'euros**, récompensera le candidat qui sera parvenu à relever ce défi précis le plus efficacement possible.

## MERCI DE VOTRE ATTENTION!

